Video Library

From the Experts

New Technologies and Effects on TURBT: Kamal Pohar, MD

Surgical practice is driven by technology.

When technology can deliver a better view of bladder cancer tumors, there’s a greater opportunity to conduct a more complete TURBT.

Challenges and Treatment of Unresponsive Disease: Ashish Kamat, MD

It is a big clinical challenge when bladder cancer is unresponsive to BCG therapy.

Dr. Kamat presents a short overview on how an incomplete TURBT could be what’s making BCG ineffective. 

Blue Light Cystoscopy with Cysview® in the Surveillance of Bladder Cancer: An Interview with Dr. Siamek Daneshmand

Dr. Sia Daneshmand joins Dr, Ashish Kamat in a conversation about the phase III trial that compared flexible Blue Light Cystoscopy with Cysview with flexible White Light Cystoscopy for the detection of bladder cancer during surveillance. This study showed that Blue Light Cystoscopy with Cysview offers significant improvement in the detection of recurrent bladder cancer and the detection of carcinoma in situ, over White Light Cystoscopy alone.

Blue Light Cystoscopy for Diagnosis of Bladder Cancer
– A Journal Club Review by Badrinath Konety

Badrinath Konety, MD, MBA presents key finding from Blue Light Cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multi-center registry published in Urologic Oncology: Seminars and Original Investigations, August 2018. This study evaluated the detection of malignant lesions in patients and documented the change in risk category due to upstaging or upgrading. The authors concluded that Blue Light Cystoscopy with Cysview significantly increases detection rates of CIS and papillary lesions compared to White Light Cystoscopy alone and can result in upstaging or upgrading in about 14% of patients. They also confirmed that repeat use of Cysview is safe.